RHRI · INDEPENDENT VALIDATION INFRASTRUCTURE
EST. 2026 · SPEC NO. RH-RI
SHEET 01 / 06
SPECIMEN — DO NOT DISCARD
RIGOROUS
SCIENCE.
REAL-WORLD
IMPACT.
RIGOROUS SCIENCE — REAL-WORLD IMPACT — RHRI — RIGOROUS SCIENCE — REAL-WORLD IMPACT — RHRI —
RIGOROUS SCIENCE — REAL-WORLD IMPACT — RHRI — RIGOROUS SCIENCE — REAL-WORLD IMPACT — RHRI —
RHRI · FINDING 001
STATUS: UNRESOLVED
SHEET 02 / 06
THE PATH
FROM LAB
TO CLINIC
IS BROKEN.
- Marketing outruns evidence.
- Clinics carry the risk.
RHRI · PROTOCOL — PILLAR ASSAY
SHEET 03 / 06
1
REPLICABILITY
Do results hold across operators, labs, geographies?
01 / 04
RHRI · PROTOCOL — PILLAR ASSAY
SHEET 03 / 06
2
SCALABILITY
Does it work at clinic volume, across real skill levels?
02 / 04
RHRI · PROTOCOL — PILLAR ASSAY
SHEET 03 / 06
3
SUSTAINABILITY
Do the economics hold as volume grows?
03 / 04
RHRI · PROTOCOL — PILLAR ASSAY
SHEET 03 / 06
4
PATIENT VALUE
Better outcomes, lower cost, wider access. The only measure that counts.
04 / 04
Most evaluations test the first. WE TEST ALL FOUR.
RHRI · SAMPLE SET A–D
SHEET 04 / 06
WHO IT'S FOR
Who it's for
INNOVATORS
Validation clinics trust.
A
CLINICS
Proven technology, less risk.
B
PATIENTS
The reason the standard exists.
C
FUNDERS
Signal, separated from noise.
D
RIGOROUS SCIENCE — REAL-WORLD IMPACT — RHRI — RIGOROUS SCIENCE — REAL-WORLD IMPACT — RHRI —
RIGOROUS SCIENCE — REAL-WORLD IMPACT — RHRI — RIGOROUS SCIENCE — REAL-WORLD IMPACT — RHRI —
RHRI · MARK OF RECORD
SHEET 05 / 06
One shared standard. Published results.
RHRI · NEXT ACTION
SHEET 06 / 06
NOW
WE BUILD.
| Daniel Madero | Founder & Director |
| Cynthia Hudson | Clinical Strategy |
| Felicitas Azpiroz | Research & Science |